Home Cart Sign in  
Chemical Structure| 836620-48-5 Chemical Structure| 836620-48-5

Structure of AS1842856
CAS No.: 836620-48-5

Chemical Structure| 836620-48-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AS-1842856 is a potent inhibitor of forkhead box class O transcription factor 1 (Foxo1) with IC50 of 33 nM in HepG2 cells which directly bind to the active Foxo1.

Synonyms: FOXO1 Inhibitor

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AS1842856

CAS No. :836620-48-5
Formula : C18H22FN3O3
M.W : 347.38
SMILES Code : O=C(C1=CN(CC)C2=C(C(N)=C(F)C(NC3CCCCC3)=C2)C1=O)O
Synonyms :
FOXO1 Inhibitor
MDL No. :MFCD30718173
InChI Key :MOMCHYGXXYBDCD-UHFFFAOYSA-N
Pubchem ID :72193864

Safety of AS1842856

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of AS1842856

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages (BMDMs) 5 μM 1 h FOXO1 inhibitor significantly attenuated LPS-induced mRNA expression levels of Tnf and Il1b in BMDMs PMC10577549
MSCs 0, 10, 20, 30 µM To evaluate the effect of iron deficiency on MSCs activity PMC11335281
neonatal rat cardiomyocytes (NRCMs) 1 μM 4 h To evaluate the effect of AS1842856 on DOX-induced Rbl2 expression, results showed that AS1842856 inhibited Rbl2 expression. PMC10308060
RAW264.7 cells 10 μM 48 h AS1842856 dramatically inhibited ARG-1 expression and promoted iNOS expression, indicating that FoxO1 plays a key role in TGF-β-induced macrophage M2-like polarization PMC6878630
mouse peritoneal macrophages 10 μM 48 h AS1842856 dramatically inhibited ARG-1 expression and promoted iNOS expression, indicating that FoxO1 plays a key role in TGF-β-induced macrophage M2-like polarization PMC6878630
BMDMs 58 nM overnight AS1842856 suppressed CD11c expression PMC10382675
THP-1 58 nM overnight AS1842856 suppressed CD11c expression PMC10382675
HL-60 58 nM overnight AS1842856 suppressed CD11c expression PMC10382675
human kidney microvascular endothelial cells (KMVECs) 0.5 μM 1 h To evaluate whether FOXO1 inhibition could restore angiogenesis, the results showed that FOXO1 inhibition significantly promoted the formation of new vessels. PMC5567800
human umbilical vein endothelial cells (HUVECs) 0.5 μM 1 h To evaluate the effect of FOXO1 inhibition on angiogenesis, the results showed that FOXO1 inhibition significantly promoted the formation of new vessels. PMC5567800

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Retinal ischemia-reperfusion injury model Intraperitoneal injection 10 mg/kg 4 consecutive days, starting 1 day before modeling AS1842856 inhibited FoxO1, alleviated RGC loss and retinal electrophysiological dysfunction induced by RIR injury, and protected retinal function by inhibiting autophagy activation. PMC11855173
Mice 18-month-old aged mice Oral gavage 10 mg/kg Daily for 5 weeks FOXO1 inhibitor significantly improved glucose homeostasis, liver fat accumulation, and systemic inflammation in old mice, and attenuated pro-inflammatory responses in hepatic macrophages PMC10577549
Mice C57BL/6 and C57BL/Ks db/db mice Intraperitoneal injection 30 μg/g Single dose, lasting 60 minutes To investigate the effect of AS1842856 on Foxo1 transcription in mouse liver, the results showed that AS1842856 eliminated 50-AMP-induced hepatic gluconeogenesis. PMC8233149
C57BL/6 mice Iron deficiency model Intraperitoneal injection, Gavage 10 mg/kg, 20 mg/kg, 50 mg/kg Daily, every 5 days, for one month To evaluate the reversal effect of AS1842856 on bone mass reduction in iron-deficient mice PMC11335281
mice DOX-induced cardiotoxicity model oral gavage 100 mg/kg twice daily for 2 days immediately after each DOX injection To evaluate the effect of AS1842856 on DOX-induced Rbl2 expression, results showed that AS1842856 inhibited Rbl2 expression. PMC10308060
mice high-fat diet-induced atherosclerosis model intraperitoneal injection 20 mg/kg 5 days a week for 8 weeks AS1842856 notably suppressed atherosclerosis and decreased CD11c expression on monocytes PMC10382675
mice ischemia reperfusion injury (IRI) model oral gavage 100 mg/kg 3 times a day for 5 days To evaluate the effect of FOXO1 inhibition on microvascular regeneration and organ function, the results showed that FOXO1 inhibition significantly improved microvascular regeneration and kidney function. PMC5567800

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.88mL

0.58mL

0.29mL

14.39mL

2.88mL

1.44mL

28.79mL

5.76mL

2.88mL

References

 

Historical Records

Categories